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Abstract
Background: Interleukin-6 (IL-6), an inflammatory cytokine, plays important roles in cerebrospinal fluid (CSF) after
subarachnoid hemorrhage (SAH). Chemokines are chemoattractant cytokines that regulate trafficking of monocytes/
macrophages and lymphocytes to sites of inflammation. However, no studies have been reported regarding the
temporal expression of these cytokines in CSF after SAH.
Findings: The concentrations of IL-6, monocyte chemoattractant protein-1 (MCP-1), interferon-γ-inducible protein-10
(IP-10), and monokine induced by interferon-γ (MIG) in the CSF of ten patients with SAH were measured using ELISA kits
over a period of 14 days. All aneurysms were located in the anterior circulation. CSF samples from patients with
unruptured aneurysms were used as controls. The concentration of IL-6 significantly increased during the acute
stage of the disease. The concentration of MCP-1 increased from days 1 to 5, peaking on day 3, and decreased
thereafter. The concentrations of IP-10 and MIG progressively increased, peaked on day 5, and then gradually
decreased. There were strong correlations between the maximum levels of IL-6 and MCP-1 and IP-10 and MIG on
day 5. The maximum level of IL-6 was much higher in poor outcome patients than in good outcome patients.
Conclusions: The present investigation demonstrated that increases in IL-6 levels may induce the expression of
MCP-1 in CSF after SAH, followed by increases in the expression of IP-10 and MIG. Dynamic changes in the levels
of these cytokines may induce inflammation and may be closely associated with the development of delayed
ischemic neurological deficits after SAH.
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Findings
Introduction
Intracisternal injections of latex beads or talc (crystal-
lized hydrous magnesium sulfate) can induce persistent
and severe cerebral vasospasm without hemorrhage,
which suggests that inflammation may play an important
role in inducing cerebral vasospasm [1–3]. Dramatically
increased levels of IL-6, a well-known inflammatory
cytokine, have been reported in CSF after SAH, a finding
suggestive of a severe inflammatory response affecting
the central nervous system (CNS) [4]. In the case of
meningitis, the CSF concentration of IL-6 is increased
[5]. Under this circumstance, patients suffering from
cerebral vasospasm also have much higher CSF concen-
trations of IL-6 [5].
Chemokines recruit leukocytes to sites of inflamma-
tion and participate in inflammatory processes. Chemo-
kine expression has been characterized in diseases of the
CNS. Increased concentrations of monocyte chemo-
attractant protein-1 (MCP-1) have been reported in the
CSF of amyotrophic lateral sclerosis patients, which sug-
gests that MCP-1 plays a role in CNS inflammation [6].
In multiple sclerosis (MS), the expression of interferon-
γ-inducible protein-10 (IP-10) in CSF is increased, while
that of MCP-1 is decreased [7]. These chemokines are
correlated with the clinical activity of MS. In the case of
SAH, MCP-1 levels in CSF have been shown to correlate
* Correspondence: kosuka@aichi-med-u.ac.jp
Department of Neurological Surgery, Aichi Medical University, 1-1
Yazakokarimata, Nagakute, Aichi 480-1195, Japan
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Niwa et al. Journal of Neuroinflammation  (2016) 13:217 
DOI 10.1186/s12974-016-0675-7
with cerebral vasospasm [8]. However, the time course
of the expression of MCP-1 and the other abovemen-
tioned inflammatory cytokines and chemokines in CSF
after SAH remains unknown. The present study was
therefore performed to elucidate the serial changes in
the concentrations of IL-6, MCP-1, IP10, and monokine
induced by interferon-γ (MIG) in the CSF after SAH.
Methods
Patients and control subjects
This study included ten patients who underwent surgical
obliteration of cerebral aneurysms at Aichi Medical
University Hospital within 1 day of the onset of SAH.
These patients, three men and seven women, ranged
from 41 to 75 years of age (mean age of 57 years). Their
baseline clinical characteristics are shown in Table 1.
After their aneurysms were clipped, cisternal catheters
were placed into their chiasmatic or prepontine cisterns,
and postoperative CSF samples were collected on each
of the following 14 days. One patient developed delayed
ischemic neurological deficits. All the other patients had
normal postoperative courses. Glasgow outcome scale
was evaluated 3 months after the onset of SAH. No pa-
tients suffered from infection. CSF samples were ob-
tained from another five patients (mean age of 62 years)
who had undergone clipping for unruptured cerebral an-
eurysms and were used as controls. All samples were
immediately centrifuged upon collection, and the super-
natants were stored at −80 °C until analysis. The Ethics
Committee of Aichi Medical University approved this
clinical experiment.
CSF analysis
The concentrations of IL-6, MCP-1, IP-10, and MIG
were measured using enzyme immunoassays (EIA; R&D
Systems, Inc., Minneapolis, MN, USA). The detection
limits of the assays were 0.70 pg/ml for IL-6, 1.7 pg/ml
for MCP-1, 1.67 pg/ml for IP-10, and 3.84 pg/ml for
MIG.
Statistical analysis
Data are expressed as the mean ± SEM. Significant dif-
ferences between groups were assessed using one-way
ANOVA, followed by Fisher’s PLSD for multiple com-
parisons. Correlations between cytokine and chemo-
kine levels were assessed by Pearson’s correlation
coefficient. Significant differences between groups
were assessed by the Mann-Whitney U test. Signifi-
cance was set at p < 0.05.
Results
Changes in IL-6, MCP-1, IP-10, and MIG levels after SAH
The concentration of IL-6 in the CSF of patients with
unruptured aneurysms was 9.7 ± 1.4 pg/ml. The concen-
tration of IL-6 increased significantly during the acute
stage of the disease, reaching a level more than 1000
times that of the control group, and then decreased
gradually thereafter (Fig. 1a). Following the increase in
the concentration of IL-6, the concentration of MCP-1
increased from days 1 to 5, peaking at day 3, and then
decreased thereafter (Fig. 1b). The concentrations of IP-
10 and MIG increased progressively, peaked on day 5,
and then decreased gradually thereafter (Fig. 1c, d). The
concentrations of MCP-1, IP-10, and MIG in the CSF of
patients with unruptured aneurysms were 732.0 ±
133.2 pg/ml, 64.2 ± 7.8 pg/ml, and 9.1 ± 3.0 pg/ml,
respectively.
The peak concentration IL-6 was positively correlated
with that of MCP-1, according to Pearson’s correlation
coefficient (r = 0.801, p < 0.05, Fig. 1e). However, no
other correlations were noted with respect to the peak
concentrations of IL-6, MCP-1, IP-10, and MIG
(Additional file 1: Table S1). It is intriguing that the con-
centration of IP-10 on day 5 was positively correlated
Table 1 Clinical data pertaining to ten patients with subarachnoid hemorrhage
Case Age, gender Location of aneurysm H & K Fisher Symptomatic vasospasm The latest sampling daya GOS
1 45, F ICPC 2 3 − 14 GR
2 71, F A. com 2 3 − 14 MD
3 53, M MCA 3 4 + 14 VD
4 65, F MCA 2 3 − 14 GR
5 49, M A. com 4 3 − 14 GR
6 75, F A. com 2 4 − 14 MD
7 41, M A. com 2 3 − 7 MD
8 46, F ICPC 2 3 − 10 GR
9 60, F A. com 3 4 − 10 GR
10 64, F A. com 4 3 − 10 MD
H & K Hunt & Kosnik grade, GOS Glasgow outcome scale, M male, F female, ICPC internal carotid-posterior communicating artery, A. com anterior communicating
artery, MCA middle cerebral artery, GR good recovery, MD moderate disability, VS vegetative state
aThe day when the last CSF was collected






























































































































r = 0.801, p < 0.05
r = 0.955, p < 0.01
Fig. 1 (See legend on next page.)
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with that of MIG on day 5, according to Pearson’s cor-
relation coefficient (r = 0.955, p < 0.01, Fig. 1f ). The peak
concentration of IL-6 increased significantly in poor out-
come (moderate disability (MD) + vegetative state (VS))
patients compared with good outcome (good recovery
(GR)) patients (Fig. 1g), while peak concentrations of all
the other chemokines showed no significance between
the two groups (Additional file 2: Table S2).
Discussion
In this study, we demonstrated that the concentration of
IL-6 increased immediately after the onset of SAH,
followed by an increase in MCP-1, whose level peaked
on day 3, and increases in IP-10 and MIG, whose levels
peaked on day 5. There were strong correlations
between the maximum levels of IL-6 and MCP-1 and
IP-10 and MIG on day 5.
We have previously shown that long-lasting cerebral
vasospasm is induced by intracisternal injections of IL-6
in canines [9]. We have also confirmed that IL-6 induces
phosphorylation of JAK1 and STAT3 in the rat basilar
artery after SAH, which transduces signals into adjacent
cell nuclei, resulting in transcription of acute-phase
genes [10]. IL-6 is a reliable early indicator of increased
vasospasm risk after SAH [11], which is in agreement
with our data indicating that poor outcome patients ex-
hibited higher IL-6 levels. IL-6 plays a role in amplifying
leukocyte accumulation at sites of inflammation by acti-
vating STAT3. This is achieved in part by augmenting
local production of MCP-1 and ICAM-1 [12]. MCP-1
belongs to the β or CC family of chemokines and stimu-
lates migration of monocytes to inflammatory tissues.
Previous studies have shown that activated mononuclear
leukocytes can be found surrounding the major cerebral
arteries in the subarachnoid space after SAH [13]. In
addition, MCP-1 has been found to be significantly
expressed in the major cerebral arteries in the setting of
cerebral vasospasm in rats [14]. Given these findings and
our data showing that a strong correlation exists be-
tween the maximum levels of IL-6 and MCP-1, immedi-
ate expression of IL-6 may play an important role in
inducing MCP-1 expression via STAT3 after SAH.
IP-10 belongs to the α or CXC family of chemokines
and was originally identified as an interferon-γ-inducible
protein. IP-10 stimulates migration of monocytes and T
cells to inflammatory tissues. However, it does not in-
duce a chemotactic activity in neutrophils. In experi-
mental autoimmune encephalomyelitis (EAE), astrocytes
were found to secrete MCP-1 and IP-10 and to play a
significant role in intrathecal inflammation [15]. MCP-1
and IP-10 are also expressed in the CSF of patients with
viral meningitis and induce chemotaxis of peripheral
blood mononuclear cells (PBMCs) [16]. MIG is also a
member of the CXC chemokine family and activates
lymphocytes. MIG and IP-10 were found to be highly
expressed in the synovial tissues of patients with
rheumatoid arthritis (RA) [17], which suggests that these
chemokines may play an important role in the patho-
physiology of RA. In the case of EAE, MIG was
expressed predominantly by macrophages/microglia,
while IP-10 was produced by astrocytes surrounding in-
flammatory lesions [18]. IP-10 and MIG have different
spatial and cellular localizations in the CNS, which sug-
gests that these chemokines have specialized functions.
We found that the concentrations of IP-10 and MIG in-
creased significantly during the first 5 days after SAH
and that there was a significant correlation between the
concentrations of IP-10 and MIG on day 5, which sug-
gests that these chemokines may play a role in the devel-
opment of delayed ischemic neurological deficits
through simultaneous activation of monocytes and lym-
phocytes. More studies are needed to explore the CNS
expression sites of these chemokines after SAH.
In wound healing, recruitment of various leukocyte
subtypes to wound sites is essential. Using a skin wound
model, macrophage migration was induced by MCP-1
expression from day 2 onward. The migration of lym-
phocytes was initiated by the expression of MCP-1 and
was accompanied by the subsequent expression of IP-10
and MIG after 4 days [19]. This time course of chemo-
kine expression is in agreement with our data, suggest-
ing that the dynamic expression of chemokines and their
subsequent recruitment of leukocyte subtypes play im-
portant roles in inflammation in the CNS after SAH.
In this study, we explored serial changes in the levels
of inflammatory cytokines and chemokines after SAH.
There were several limitations to this study. We enrolled
only a small number of patients of widely varying ages
(See figure on previous page.)
Fig. 1 Dynamic changes in the levels of interleukin-6 (IL-6; a), monocyte chemoattractant protein-1 (MCP-1; b), interferon-γ-inducible protein-10
(IP-10; c), and monokine induced by interferon-γ (MIG; d) in the cerebrospinal fluid of ten patients with subarachnoid hemorrhage. Data are
represented as box-and-whisker plots indicating the median, the upper and lower quartiles, and the largest and the lowest values. *p < 0.05
compared with control group via one-way ANOVA, followed by Fisher’s PLSD for multiple comparisons. The correlations between the peak concentration
of IL-6 and that of MCP-1 (e) and the concentrations of IP-10 and MIG on day 5 (f), according to Pearson’s correlation coefficient. The open circle represents
the data from the good outcome (good recovery (GR)) patients, while the closed circle represents the data from the poor outcome (moderate disability
(MD) + vegetative state (VS)) patients. Peak concentrations of IL-6 (g) in the good outcome (GR) patients and poor outcome (MD+ VS) patients. *p< 0.05
by Mann-Whitney U test
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and with widely varying outcomes. It is possible that
these factors affected the cytokine concentrations in the
CSF of these patients. Moreover, our results are purely
observational, as we performed no animal experiments
to corroborate our findings. Only one patient in this
study suffered from symptomatic vasospasm; therefore,
it is unclear whether the abovementioned cytokines play
roles in the pathogenesis of delayed ischemic neurologic
deficits after SAH. The sample size was not large enough
to allow patient subgroup analyses. Our preliminary data
confirmed only that strong correlations exist between
the maximum levels of IL-6 and MCP-1 and IP-10 and
MIG on day 5 after SAH. Additional studies involving
larger numbers of patients are necessary to determine
whether these factors are associated with the develop-
ment of delayed brain injury after SAH.
Conclusion
This study showed for the first time the dynamic
changes that occur in the concentrations of inflamma-
tory cytokines and chemokines in CSF after SAH. Our
finding regarding the sequential expression of cytokines
and chemokines in CSF after SAH was particularly inter-
esting, as it suggests that these molecules may be in-
volved in the development of delayed ischemic
neurologic deficits. Especially, IL-6 was one of the fac-
tors of poor prognosis. More data are needed to deter-
mine if there is a difference in the expression levels of
these chemokines between symptomatic and asymptom-
atic patients and to elucidate the mechanism underlying
the sequential expression of these chemokines. Thera-
peutic interventions targeting these chemokines may
provide a means of treating delayed ischemic neurologic
deficits after SAH.
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